Key facts
- This page summarizes Michael Egholm's Form 4 filing for STANDARD BIOTOOLS INC. (LAB).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 24 Mar 2025, 18:31.
Michael Egholm - 21 Mar 2025 Form 4 Insider Report for STANDARD BIOTOOLS INC. (LAB)
- Reporting relationship
- President & CEO, Director
- Issuer ticker
- LAB
- Reported as of
- 21 Mar 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 24 Mar 2025, 18:31:57 UTC
- Prior SEC filing
- 24 Feb 2025
- Next SEC filing
- 08 Apr 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Michael Egholm by Tomone Tanaka, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Michael Egholm filed Form 4 for STANDARD BIOTOOLS INC. (LAB) on 24 Mar 2025.
Change
- Previous filing in this sequence was filed on 24 Feb 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
LAB
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +1,188,333
- Change %
- +82%
- Price
- $0.000000
- Shares after
- 2,636,006
- Date
- 21 Mar 2025
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
LAB
transaction
Derivative
Stock Option (Right to buy)
Award
- Transaction value
- $0
- Shares
- +1,782,500
- Change %
- Price
- $0.000000
- Shares after
- 1,782,500
- Date
- 21 Mar 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,782,500
- Exercise price
- $1.21
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Represents restricted stock units ("RSUs") that vest over four years, with 1/16 of the RSUs vesting on May 20, 2025 and the remaining RSUs vesting in equally quarterly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the right to receive one share of common stock upon vesting.
Footnote F2
The Option becomes exercisable as to 1/16th of the underlying shares on May 20, 2025, with the remaining shares vesting in equally quarterly installments, thereafter, subject to the Reporting Person's continued service through the applicable vesting date.